Stay updated on GB1275 Monotherapy and with Anti-PD1 in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the GB1275 Monotherapy and with Anti-PD1 in Solid Tumors Clinical Trial page.

Latest updates to the GB1275 Monotherapy and with Anti-PD1 in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 on the page, with no apparent changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedThe page no longer displays the government funding/operating status notice; core study details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedNo significant changes detected on the Study Details page; core information such as the NCT ID, title, sponsor, design, eligibility, and locations remains the same.SummaryDifference0.3%

- Check71 days agoChange DetectedAdd important status notice and new version tag; remove a specific disease name and old version tag. Overall, the page becomes more informative about operating status and current version, while dropping a now-irrelevant disease mention.SummaryDifference3%

- Check78 days agoChange DetectedAdded version v3.1.0 and removed the term 'head and neck squamous cell carcinoma', plus the older version v3.0.2. Overall, a version update with targeted content removal.SummaryDifference0.3%

- Check93 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; 'Back to Top' link removed. Overall, a minor change with no impact on core content or user-facing data.SummaryDifference0.2%

Stay in the know with updates to GB1275 Monotherapy and with Anti-PD1 in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GB1275 Monotherapy and with Anti-PD1 in Solid Tumors Clinical Trial page.